We report two cases of multiple sclerosis (MS) patients with natalizumab-associated progressive multifocal leukoencephalopathy. Severe MS relapses occurred between four and five months after natalizumab discontinuation. After failure of immunomodulatory treatment, both patients were treated with fingolimod. The outcome was positive on clinical and MRI disease activity, without worsening of the progressive multifocal leukoencephalopathy. These observations suggest that using fingolimod for severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy may be an option, under close clinical and radiological monitoring.
PolmanCHO’ConnorPWHavrdovaE. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
2.
CliffordDBDe LucaASimpsonDM. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol2010; 9: 438–446.
3.
WestTWCreeBA. Natalizumab dosage suspension: Are we helping or hurting?Ann Neurol2010; 68: 395–399.
4.
MagranerMJCoretFNavarreA. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: A prospective, 6-month observational study. J Neurol2011; 258: 1805–1811.
5.
KapposLRadueEWO’ConnorP. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
6.
HavlaJTackenbergBHellwigK. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol2013; 260: 1382–1387.
7.
CohenJABarkhofFComiG. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
8.
CohenJAChunJ. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol2011; 69: 759–777.
9.
MehlingMBrinkmannVAntelJ. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology2008; 71: 1261–1267.
